Hospitals Segment is Expected to be Fastest Growing During Forecast Period for SAM Region     

According to a new market research study on “SAM Diabetic Foot Ulcer Treatment Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type, Ulcer Type, and End User” is expected to reach US$ 385.79 million by 2028 from US$ 243.21 million in 2021. The market is estimated to grow at a CAGR of 6.8% from 2021 to 2028. The report provides trends prevailing in the SAM diabetic foot ulcer treatment market along with the drivers and restraints pertaining to the market growth. Increasing prevalence of diabetes and related chronic wounds and use of 3D printing in wound care management are the major factor driving the growth of the SAM diabetic foot ulcer treatment market. However, overpriced advanced wound care treatments hinders the growth of SAM diabetic foot ulcer treatment market.        

In case of COVID-19, SAM is highly affected especially Brazil. Many SAM countries have faced shortages of resources to manufacture and supply medical products. Some of the hard-hit countries such as Brazil, where case number surpassed 13,601,566, and Argentina, the case recorded as 2,579,000 as of May 2021. It is expected that the region is likely to impose a second lockdown, which will eventually hamper the healthcare industry in the area. COVID-19 continues to have a tremendous impact on the region. Although Peru established one of the strictest lockdowns in the SAM region, it suffered the highest mortality rate due to COVID-19. The coronavirus pandemic has become an enormous challenge to this region, as they are low-cost regions. Over the past few months, the region has implemented telehealth strategies. For instance, in March 2020, Brazilian Ministry of health recommended telemedicine as medical practice for wound and injury care, education and health promotion purposes. The Centro de Referência Estadual para a Assistência ao Diabetes e Endocrinologia (CEDEBA) located in Salvador, Bahia in Brazil have created a structured screening system for patients who need care for diabetic foot ulcer treatment. These factors are expected support market for diabetic foot ulcer treatment market in this region. However, in 2021, vaccination was made available in the region, due to which the number of infected persons is expected to come down, thereby boosting the economy and helping the wound care industry to recover in this region.

The SAM diabetic foot ulcer treatment market is segmented based on the type, ulcer type, end user, and country. Based on type, the market has been segmented into the advanced wound care dressings, biologics, and therapy device. The advanced wound care dressings segment dominated the SAM diabetic foot ulcer treatment market in 2020 and biologics segment is expected to be fastest growing during forecast. Further, advanced wound care dressings is segmented into hydrogel dressings, collagen dressing, alginate dressings, foam dressings, hydrocolloid dressings, and others. Further, biologics is segmented into the skin grafts and growth factors. Similarly, therapy device is segmented into negative pressure wound therapy and ultrasound therapy. Based on ulcer type, the market has been segmented into neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. The neuro-ischemic ulcers segment dominated the SAM diabetic foot ulcer treatment market in 2020 and same segment is expected to be fastest growing during forecast. Moreover, based on end user, the market has been segmented into the hospitals, ambulatory surgery centers, and home care. The hospital segment dominated the SAM diabetic foot ulcer treatment market in 2020 and same segment is expected to be fastest growing during forecast. Based on country, the market has been segmented into Brazil, Argentina, and rest of SAM. 

3M; B. Braun Melsungen AG; Cardinal Health Inc; Coloplast Group; ConvaTec Group Plc; Medline Industries, Inc.; Mölnlycke Health Care AB.; Organogenesis Inc.; Smith & Nephew; and URGO are among the leading companies in the SAM diabetic foot ulcer treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2019, Organogenesis Holdings Inc. and Vizient, Inc. has entered partnership for development, manufacture and commercialization of product solutions for the advanced wound care. This partnership is expected to expand customer base for the Organogenesis as Vizient, Inc. has network of more than 3,100 hospitals in North America.                         

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com